(HealthDay News) — For patients with heart failure with reduced ejection fraction and predominantly central sleep apnea, adaptive servo-ventilation does not improve outcome, according to a study ...

Please provide your email address to receive an email when new articles are posted on . Treatment with adaptive servo-ventilation for 12 months improved disease-specific quality of life scores. At 12 ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — In a substudy of CAT-HF, patients with HF, sleep-disordered breathing and an implantable cardiac ...

MONTREAL — The treatment of central sleep apnea in heart failure patients was in the spotlight here at CHEST 2015, as experts debated whether or not to completely reject the use of adaptive servo ...

To the Editor: Cowie et al. (Sept. 17 issue) 1 report on the results of the Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients with ...

European Respiratory & Pulmonary Diseases, 2016;2(1):Epub ahead of print DOI: http://doi.org/10.17925/ERPD.2016.02.01.1 (Logo: http://photos.prnewswire.com/prnh ...

On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...

The results of the first randomized, controlled trial to assess adaptive servo-ventilation (ASV) for central sleep apnoea were expected to confirm the positive findings from previous observational ...

ResMed announced primary results from a multicenter, randomized controlled phase II trial known as CAT-HF presented at the European Society of Cardiology's 2016 Annual Heart Failure Congress. CAT-HF ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

SAN DIEGO, May 13, 2015 /CNW/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was ...

SAN DIEGO, May 13, 2015 /PRNewswire/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint.